JP2008514187A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008514187A5 JP2008514187A5 JP2007530180A JP2007530180A JP2008514187A5 JP 2008514187 A5 JP2008514187 A5 JP 2008514187A5 JP 2007530180 A JP2007530180 A JP 2007530180A JP 2007530180 A JP2007530180 A JP 2007530180A JP 2008514187 A5 JP2008514187 A5 JP 2008514187A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- seq
- individual
- administering
- nucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims description 107
- 125000003729 nucleotide group Chemical group 0.000 claims description 86
- 239000002773 nucleotide Substances 0.000 claims description 85
- 238000000034 method Methods 0.000 claims description 64
- 208000023275 Autoimmune disease Diseases 0.000 claims description 29
- 208000027866 inflammatory disease Diseases 0.000 claims description 24
- 230000028993 immune response Effects 0.000 claims description 17
- 230000001419 dependent effect Effects 0.000 claims description 16
- 208000024891 symptom Diseases 0.000 claims description 12
- 230000016396 cytokine production Effects 0.000 claims description 11
- 230000004044 response Effects 0.000 claims description 11
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims description 10
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 9
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 8
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 8
- 229930010555 Inosine Natural products 0.000 claims description 8
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 8
- 102100033117 Toll-like receptor 9 Human genes 0.000 claims description 8
- 229960003786 inosine Drugs 0.000 claims description 8
- 230000015788 innate immune response Effects 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims description 4
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 229940029575 guanosine Drugs 0.000 claims description 4
- 244000052769 pathogen Species 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 210000000987 immune system Anatomy 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 239000002719 pyrimidine nucleotide Substances 0.000 claims description 2
- 150000003230 pyrimidines Chemical class 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- 230000003053 immunization Effects 0.000 claims 2
- NJZHEQOUHLZCOX-ZENOOKHLSA-N (3aR,4R,9bS)-golgicide A Chemical compound C1([C@@H]2NC3=C(F)C=C(C=C3[C@H]3C=CC[C@H]32)F)=CC=CN=C1 NJZHEQOUHLZCOX-ZENOOKHLSA-N 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 30
- 210000004989 spleen cell Anatomy 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 12
- 229950010550 resiquimod Drugs 0.000 description 11
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
- 230000017306 interleukin-6 production Effects 0.000 description 9
- 102000004889 Interleukin-6 Human genes 0.000 description 8
- 108090001005 Interleukin-6 Proteins 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 102000005309 phosducin Human genes 0.000 description 8
- 108010031256 phosducin Proteins 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 7
- 230000011488 interferon-alpha production Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241000712461 unidentified influenza virus Species 0.000 description 5
- 102000006992 Interferon-alpha Human genes 0.000 description 4
- 108010047761 Interferon-alpha Proteins 0.000 description 4
- 101100019396 Mus musculus Itgax gene Proteins 0.000 description 4
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 4
- -1 phosphorothioate ester Chemical class 0.000 description 4
- VDCRFBBZFHHYGT-IOSLPCCCSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-3h-purine-6,8-dione Chemical compound O=C1N(CC=C)C=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VDCRFBBZFHHYGT-IOSLPCCCSA-N 0.000 description 3
- 102000002689 Toll-like receptor Human genes 0.000 description 3
- 108020000411 Toll-like receptor Proteins 0.000 description 3
- 229950005634 loxoribine Drugs 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 102100022297 Integrin alpha-X Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000019734 interleukin-12 production Effects 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- 208000037952 HSV-1 infection Diseases 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 102100035254 Sodium- and chloride-dependent GABA transporter 3 Human genes 0.000 description 1
- 101710104417 Sodium- and chloride-dependent GABA transporter 3 Proteins 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000007302 negative regulation of cytokine production Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60683304P | 2004-09-01 | 2004-09-01 | |
| PCT/US2005/030494 WO2006028742A2 (en) | 2004-09-01 | 2005-08-24 | Methods and conpositions for inhibition of innate immune responses and autoimmunity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012129374A Division JP5775024B2 (ja) | 2004-09-01 | 2012-06-06 | 先天性免疫応答及び自己免疫疾患の阻害法及び阻害用組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008514187A JP2008514187A (ja) | 2008-05-08 |
| JP2008514187A5 true JP2008514187A5 (https=) | 2008-10-23 |
Family
ID=36036819
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007530180A Pending JP2008514187A (ja) | 2004-09-01 | 2005-08-24 | 先天性免疫応答及び自己免疫疾患の阻害法及び阻害用組成物 |
| JP2012129374A Expired - Fee Related JP5775024B2 (ja) | 2004-09-01 | 2012-06-06 | 先天性免疫応答及び自己免疫疾患の阻害法及び阻害用組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012129374A Expired - Fee Related JP5775024B2 (ja) | 2004-09-01 | 2012-06-06 | 先天性免疫応答及び自己免疫疾患の阻害法及び阻害用組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8759305B2 (https=) |
| EP (2) | EP1794174B1 (https=) |
| JP (2) | JP2008514187A (https=) |
| KR (1) | KR101268877B1 (https=) |
| CN (1) | CN101052643B (https=) |
| AU (2) | AU2005282889B2 (https=) |
| CA (1) | CA2578775C (https=) |
| DK (1) | DK1794174T3 (https=) |
| ES (2) | ES2385657T3 (https=) |
| NZ (1) | NZ553581A (https=) |
| PL (1) | PL1794174T3 (https=) |
| PT (1) | PT1794174E (https=) |
| SI (1) | SI1794174T1 (https=) |
| WO (1) | WO2006028742A2 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008514187A (ja) | 2004-09-01 | 2008-05-08 | ダイナバックス テクノロジーズ コーポレイション | 先天性免疫応答及び自己免疫疾患の阻害法及び阻害用組成物 |
| EP1836218A2 (en) * | 2004-12-17 | 2007-09-26 | Dynavax Technologies Corporation | Methods and compositions for induction or promotion of immune tolerance |
| DE102005005642A1 (de) * | 2005-02-06 | 2006-08-10 | Phenion Gmbh & Co. Kg | Kosmetische oder pharmazeutische Zubereitungen enthaltend Nukleinsäuren, die zur Ausbildung von stem-loop-Sekundärstrukturen geeignete Sequenzen umfassen |
| AU2006220835B2 (en) | 2005-03-04 | 2012-01-19 | Dynavax Technologies Corporation | Vaccines comprising oligonucleotides having immunostimulatory sequences (ISS) wherein the ISS are conjugated to antigens and stabilized by buffer conditions and further excipients |
| WO2007004977A1 (en) | 2005-07-01 | 2007-01-11 | Index Pharmaceuticals Ab | Immunostimulatory method |
| PL2179737T3 (pl) | 2005-07-01 | 2014-01-31 | Index Pharmaceuticals Ab | Sposób do modulowania wrażliwości na steroidy |
| ES2544877T3 (es) | 2005-10-12 | 2015-09-04 | Idera Pharmaceuticals | Compuestos oligonucleótidos inmuno reguladores (IRO) para modular la respuesta inmune basada en receptor semejante a Toll |
| CA2625969A1 (en) | 2005-10-28 | 2007-05-03 | Index Pharmaceuticals Ab | Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease |
| MX2010001785A (es) * | 2007-08-15 | 2010-03-10 | Idera Pharmaceuticals Inc | Moduladores de receptores tipo larga distancia. |
| CA2703931C (en) | 2007-10-26 | 2016-08-16 | Dynavax Technologies Corporation | Methods and compositions for inhibition of immune responses and autoimmunity |
| US8030289B2 (en) * | 2008-08-06 | 2011-10-04 | Changchun Huapu Biotechnology Co., Ltd. | Oligonucleotide and use thereof |
| PL2154144T3 (pl) * | 2008-08-06 | 2015-04-30 | Changchun Huapu Biotechnology Co Ltd | Oligonukleotydy i ich zastosowanie |
| AU2009302468A1 (en) * | 2008-10-06 | 2010-04-15 | Idera Pharmaceuticals, Inc. | Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto |
| WO2011005942A2 (en) * | 2009-07-08 | 2011-01-13 | Idera Pharmaceuticals, Inc. | Oligonucleotide-based compounds as inhibitors of toll-like receptors |
| CN103153346A (zh) * | 2010-06-16 | 2013-06-12 | 戴纳瓦克斯技术公司 | 使用tlr7和/或tlr9抑制剂的治疗方法 |
| JP5921535B2 (ja) * | 2010-06-16 | 2016-05-24 | ディナバックス テクノロジーズ コーポレイション | Ｔｌｒ７および／またはｔｌｒ９阻害剤を用いる治療の方法 |
| BR112013005872A2 (pt) | 2010-09-22 | 2019-09-24 | Alios Biopharma Inc | compostos, composição farmacêutica e respectivos usos |
| KR101985382B1 (ko) | 2010-11-19 | 2019-06-03 | 이데라 파마슈티칼즈, 인코포레이티드 | 톨-유사 수용체 기반 면역 반응을 조절하기 위한 면역 조절 올리고뉴클레오타이드(ｉｒｏ) 화합물 |
| EP2794630A4 (en) | 2011-12-22 | 2015-04-01 | Alios Biopharma Inc | SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE |
| WO2013142124A1 (en) | 2012-03-21 | 2013-09-26 | Vertex Pharmaceuticals Incorporated | Solid forms of a thiophosphoramidate nucleotide prodrug |
| US9012427B2 (en) | 2012-03-22 | 2015-04-21 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
| US9228184B2 (en) * | 2012-09-29 | 2016-01-05 | Dynavax Technologies Corporation | Human toll-like receptor inhibitors and methods of use thereof |
| US9868955B2 (en) | 2012-09-29 | 2018-01-16 | Dynavax Technologies Corporation | Human toll-like receptor inhibitors and methods of use thereof |
| EP2754714A1 (en) * | 2013-01-14 | 2014-07-16 | Sarepta Therapeutics, Inc. | Inhibitory oligonucleotides and their use in therapy |
| US10849917B2 (en) | 2015-06-01 | 2020-12-01 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in type VII collagen |
| WO2017173334A1 (en) | 2016-04-01 | 2017-10-05 | Checkmate Pharmaceuticals, Inc. | Fc receptor-mediated drug delivery |
| US11339396B2 (en) | 2016-06-08 | 2022-05-24 | President And Fellows Of Harvard College | Engineered viral vector reduces induction of inflammatory and immune responses |
| US11370794B2 (en) | 2016-11-11 | 2022-06-28 | Dynavax Technologies Corporation | Toll-like receptor antagonist compounds and methods of use |
| JP6886854B2 (ja) * | 2017-04-13 | 2021-06-16 | シスメックス株式会社 | 被検物質の情報取得方法 |
| AU2018364542A1 (en) | 2017-11-08 | 2020-04-16 | President And Fellows Of Harvard College | Compositions and methods for inhibiting viral vector-induced inflammatory responses |
| US12246031B2 (en) | 2018-02-13 | 2025-03-11 | Checkmate Pharmaceuticals, Inc. | Compositions and methods for tumor immunotherapy |
| KR102890791B1 (ko) | 2018-04-09 | 2025-11-24 | 체크메이트 파마슈티칼스, 인크. | 바이러스-유사 입자 내로의 올리고뉴클레오타이드의 포장 |
| US11863189B2 (en) * | 2021-03-05 | 2024-01-02 | Taiwan Semiconductor Manufacturing Company, Ltd. | Input buffer circuit |
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) * | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4948882A (en) * | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
| US4650675A (en) | 1983-08-18 | 1987-03-17 | The Children's Medical Center Corporation | Oligonucleotide conjugates |
| US5118802A (en) * | 1983-12-20 | 1992-06-02 | California Institute Of Technology | DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside |
| US5118800A (en) * | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
| US5015733A (en) * | 1983-12-20 | 1991-05-14 | California Institute Of Technology | Nucleosides possessing blocked aliphatic amino groups |
| US4849513A (en) | 1983-12-20 | 1989-07-18 | California Institute Of Technology | Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups |
| US4587329A (en) | 1984-08-17 | 1986-05-06 | The Dow Chemical Company | Dense star polymers having two dimensional molecular diameter |
| US4910300A (en) | 1985-12-11 | 1990-03-20 | Chiron Corporation | Method for making nucleic acid probes |
| US5093232A (en) | 1985-12-11 | 1992-03-03 | Chiron Corporation | Nucleic acid probes |
| US5338532A (en) * | 1986-08-18 | 1994-08-16 | The Dow Chemical Company | Starburst conjugates |
| US6312679B1 (en) | 1986-08-18 | 2001-11-06 | The Dow Chemical Company | Dense star polymer conjugates as dyes |
| KR970005898B1 (ko) | 1987-09-21 | 1997-04-21 | 젠- 프로우브 인코퍼레이티드 | 뉴클레오티드 프로브에 대한 비-뉴클레오티드 연결시약 |
| US5124246A (en) * | 1987-10-15 | 1992-06-23 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
| US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
| US5391723A (en) * | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
| US5552391A (en) | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| US5171264A (en) | 1990-02-28 | 1992-12-15 | Massachusetts Institute Of Technology | Immobilized polyethylene oxide star molecules for bioapplications |
| US5460831A (en) | 1990-06-22 | 1995-10-24 | The Regents Of The University Of California | Targeted transfection nanoparticles |
| US6096722A (en) * | 1990-08-14 | 2000-08-01 | Isis Pharmaceuticals Inc. | Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases |
| WO1995006731A2 (en) | 1993-09-02 | 1995-03-09 | Ribozyme Pharmaceuticals, Inc. | Non-nucleotide containing enzymatic nucleic acid |
| US5874409A (en) | 1995-06-07 | 1999-02-23 | La Jolla Pharmaceutical Company | APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies |
| KR20000016414A (ko) | 1996-06-06 | 2000-03-25 | 와이즈먼 앤드루 | Apl 면역반응성 펩티드, 그것의 콘주게이트 및 apl항체-매개병변의 치료방법 |
| ES2241042T3 (es) | 1996-10-11 | 2005-10-16 | The Regents Of The University Of California | Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora. |
| US6489304B2 (en) * | 1997-05-01 | 2002-12-03 | Hybridon, Inc. | Hyperstructure-forming carriers |
| WO1998055495A2 (en) | 1997-06-06 | 1998-12-10 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
| US6080580A (en) * | 1998-10-05 | 2000-06-27 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide modulation of tumor necrosis factor-α (TNF-α) expression |
| US6458953B1 (en) | 1998-12-09 | 2002-10-01 | La Jolla Pharmaceutical Company | Valency platform molecules comprising carbamate linkages |
| AU4343700A (en) | 1999-04-12 | 2000-11-14 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Oligodeoxynucleotide and its use to induce an immune response |
| KR20020022691A (ko) | 1999-06-08 | 2002-03-27 | 와이즈먼 앤드루 | 아미노옥시기를 포함하는 원자가 플랫폼 분자 |
| SK287400B6 (sk) | 1999-09-25 | 2010-08-09 | University Of Iowa Research Foundation | Prostriedok s obsahom imunostimulačnej nukleovej kyseliny a jeho použitie na stimuláciu imunitnej reakcie |
| US7585847B2 (en) * | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
| US7291330B2 (en) | 2000-03-17 | 2007-11-06 | Trillium Therapeutics Inc. | MD-1 inhibitors as immune suppressants |
| US6498013B1 (en) * | 2000-07-28 | 2002-12-24 | The Johns Hopkins University | Serial analysis of transcript expression using MmeI and long tags |
| JP4049357B2 (ja) | 2000-08-11 | 2008-02-20 | 独立行政法人科学技術振興機構 | ポルフィリン環が互いにメゾ−メゾ炭素結合と２つのβ−β炭素の結合との三つの結合により一方向に縮環したポルフィリン化合物およびその合成方法 |
| CA2441417A1 (en) | 2001-03-21 | 2002-11-14 | Human Genome Sciences, Inc. | Human secreted proteins |
| WO2003085110A2 (en) | 2002-04-05 | 2003-10-16 | Santaris Pharma A/S | Oligomeric compounds for the modulation hif-1alpha expression |
| WO2003103586A2 (en) | 2002-06-05 | 2003-12-18 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids |
| SE0201701D0 (sv) | 2002-06-05 | 2002-06-05 | Gotovax Ab | Treatment of epithelial tumors and infections |
| US20040053880A1 (en) * | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| NZ538628A (en) * | 2002-08-12 | 2008-06-30 | Dynavax Tech Corp | Immunomodulatory compositions, methods of making, and methods of use thereof |
| EP2298360A3 (en) | 2002-11-21 | 2011-07-13 | Bayhill Therapeutics, Inc. | Methods and immune modulatory nucleic acid compositions for preventing and treating disease |
| PT1992635E (pt) * | 2002-12-23 | 2012-03-20 | Dynavax Tech Corp | Oligonucleótidos de sequência imunoestimuladora e métodos de utilização dos mesmos |
| US20070009899A1 (en) * | 2003-10-02 | 2007-01-11 | Mounts William M | Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases |
| US20050239733A1 (en) * | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
| AU2005220910A1 (en) | 2004-03-05 | 2005-09-22 | Archemix Corp. | Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics |
| US20060193821A1 (en) * | 2004-03-05 | 2006-08-31 | Diener John L | Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics |
| JP2008514187A (ja) | 2004-09-01 | 2008-05-08 | ダイナバックス テクノロジーズ コーポレイション | 先天性免疫応答及び自己免疫疾患の阻害法及び阻害用組成物 |
| EP1836218A2 (en) * | 2004-12-17 | 2007-09-26 | Dynavax Technologies Corporation | Methods and compositions for induction or promotion of immune tolerance |
| US7786089B2 (en) | 2005-12-20 | 2010-08-31 | Idera Pharmaceuticals, Inc. | Immunostimulatory activity of immune modulatory oligonucleotides (IMO™) containing different lengths of palindromic segments |
| EP1986697B1 (en) | 2006-02-17 | 2016-06-29 | GE Healthcare Dharmacon, Inc. | Compositions and methods for inhibiting gene silencing by rna interference |
| EP2021008B1 (en) | 2006-04-07 | 2015-12-02 | Idera Pharmaceuticals, Inc. | Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8 |
| CA2703931C (en) * | 2007-10-26 | 2016-08-16 | Dynavax Technologies Corporation | Methods and compositions for inhibition of immune responses and autoimmunity |
-
2005
- 2005-08-24 JP JP2007530180A patent/JP2008514187A/ja active Pending
- 2005-08-24 SI SI200531556T patent/SI1794174T1/sl unknown
- 2005-08-24 ES ES05792518T patent/ES2385657T3/es not_active Expired - Lifetime
- 2005-08-24 EP EP05792518A patent/EP1794174B1/en not_active Expired - Lifetime
- 2005-08-24 PT PT05792518T patent/PT1794174E/pt unknown
- 2005-08-24 KR KR1020077006947A patent/KR101268877B1/ko not_active Expired - Fee Related
- 2005-08-24 WO PCT/US2005/030494 patent/WO2006028742A2/en not_active Ceased
- 2005-08-24 AU AU2005282889A patent/AU2005282889B2/en not_active Ceased
- 2005-08-24 CN CN200580037417.4A patent/CN101052643B/zh not_active Expired - Fee Related
- 2005-08-24 ES ES10011096.4T patent/ES2543207T3/es not_active Expired - Lifetime
- 2005-08-24 NZ NZ553581A patent/NZ553581A/en not_active IP Right Cessation
- 2005-08-24 CA CA2578775A patent/CA2578775C/en not_active Expired - Lifetime
- 2005-08-24 EP EP10011096.4A patent/EP2305693B1/en not_active Expired - Lifetime
- 2005-08-24 DK DK05792518.2T patent/DK1794174T3/da active
- 2005-08-24 US US11/212,297 patent/US8759305B2/en active Active
- 2005-08-24 PL PL05792518T patent/PL1794174T3/pl unknown
-
2012
- 2012-05-29 AU AU2012203156A patent/AU2012203156B2/en not_active Ceased
- 2012-06-06 JP JP2012129374A patent/JP5775024B2/ja not_active Expired - Fee Related
-
2014
- 2014-06-23 US US14/312,533 patent/US20150050296A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008514187A5 (https=) | ||
| Jacobsen et al. | Eosinophil knockout humans: uncovering the role of eosinophils through eosinophil-directed biological therapies | |
| Barron et al. | The spectrum of the deficiency of adenosine deaminase 2: an observational analysis of a 60 patient cohort | |
| Ma et al. | Immunological abnormalities in patients with primary biliary cholangitis | |
| Romme Christensen et al. | Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis | |
| Jesus et al. | IL-1 blockade in autoinflammatory syndromes | |
| EP2901856B1 (en) | Immunostimulatory oligonucleotide multimers | |
| JP6151746B2 (ja) | アルツハイマー病の予防又は治療のためのｉｌ−１２及び／又はｉｌ−２３のモジュレーター | |
| US7498425B2 (en) | Immunostimulatory oligonucleotide multimers | |
| WO2017079352A2 (en) | Compositions for inhibiting nlrp3 gene expression and uses thereof | |
| Vyas et al. | Immune correlates of hepatitis B surface antigen spontaneous seroconversion in hepatitis B e antigen negative chronic hepatitis B patients | |
| Kacem et al. | Elevated expression of TSLP and IL-33 in Behçet's disease skin lesions: IL-37 alleviate inflammatory effect of TSLP | |
| US12514913B2 (en) | Method for treating fibromyalgia and chronic fatigue syndrome | |
| JP2008544983A (ja) | 免疫促進方法 | |
| Fazazi et al. | Myelin-reactive B cells exacerbate CD4+ T cell-driven CNS autoimmunity in an IL-23-dependent manner | |
| Niu et al. | Regulatory immune responses induced by IL-1 receptor antagonist in rheumatoid arthritis | |
| Wang et al. | Role of eosinophils in a murine model of inflammatory bowel disease | |
| Lluch et al. | Development of leprosy in a patient with rheumatoid arthritis during treatment with etanercept: a case report | |
| JP2018504909A5 (https=) | ||
| Sadeghnejad et al. | Exploring the role of mesenchymal stem cells in modulating immune responses via Treg and Th2 cell activation: insights from mouse model of multiple sclerosis | |
| JP2012507308A (ja) | Ｃｎｓの炎症性疾患の治療のための化合物および方法 | |
| CN111012783A (zh) | 自噬抑制剂在制备抑制嗜碱性粒细胞活化的药物中的应用 | |
| Horiuchi et al. | Heightened IgE response to mite antigens in inflammatory neuropathies | |
| WO2015187704A1 (en) | Dgat1 inhibition for treatment of demyelinating inflammatory disease | |
| US9850492B2 (en) | Aptamer to IL-17 and use thereof |